Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYCS | P99999 | 4/20 | 0.97 |
| ▸ | TOP1 | P11387 | 4/20 | 0.78 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684505 | 0.92 | CYCS (0.83) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL14246889 | 0.92 | CYCS (0.83) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL30999674 | 0.90 | CYCS (0.80) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL12842181 | 0.89 | CYCS (0.97) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL26089781 | 0.89 | CYCS (0.78) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL25392157 | 0.88 | CYCS (0.83) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL709532 | 0.88 | TOP1 (1.00) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL29354037 | 0.88 | TOP1 (1.00) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL17183606 | 0.86 | TOP1 (0.97) | CYCSTOP1ENPP2ABCG2TERT | |
| SCHEMBL19640853 | 0.86 | CYCS (1.00) | CYCSTOP1ENPP2ABCG2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064694-A1 | ANTI-HEPATITIS C ACTIVITY OF MESO-TETRAKIS-PORPHYRIN ANALOGUES | YALE UNIVERSITY (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064694-A1 | ANTI-HEPATITIS C ACTIVITY OF MESO-TETRAKIS-PORPHYRIN ANALOGUES | HAVCR2, HCCS, HMBS | CYCS 33/4885TOP1 2148/4885ENPP2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.